She had a waddling gait and was unable to rise from a chair without using her arms. Facial and bulbar muscles were not involved but there was moderate generalized weakness of the limbs and loss of tendon jerks. Plantar reflexes were flexor. There was no sensory loss. The peripheral nerves were not thickened and were not found to be so at any subsequent examination.
The cerebrospinal fluid protein was 75 mg/100 ml. with no increase in cells. Full blood count was normal and sedimentation rate was 3 mm in the first hour. The following investigations were normal: serum proteins, electrolytes, calcium and phosphate, cholesterol, liver function tests, vitamin B12, blood urea, faecal fat, urinary hydroxyindoles, and glucose tolerance. Radiographs of the chest and barium meal revealed no abnormality. No LE cells 'Present address: the Manchester Royal Infirmary. "Present address: Newcastle General Hospital.
were present in the peripheral blood. The urine was normal.
Treatment with prednisolone 30 mg a day was begun on 21 January 1963. Subsequent dosage and the clinical state are shown in Fig. 1 . An increase in strength was noted two weeks from the beginning of treatment and after six weeks an attempt at stopping treatment was followed by a relapse in which walking unaided was difficult. The dose was increased with some further improvement but treatment was stopped in July 1963 as she was extremely moon faced. There was little change in her condition until April 1964 when weakness increased and for the first time sensory loss was found, consisting of slight changes to light touch in the hands. She was readmitted in May 1964 with severe generalized weakness of the limbs. The cerebrospinal fluid (CSF) protein was now 100 mg/100 ml. Prednisolone 30 mg a day was begun and continued in a lower dose. Improvement was noted three weeks later and was maintained until December 1964 when, while on 10 mg prednisolone a day, there was a severe relapse. The dose was immediately increased to 40 mg a day but was difficult to maintain at this level because of extremely marked hypercorticoidism. On 20 mg a day no improvement occurred.
From the onset of the disease she had suffered from 'attacks'. At first she described these as palpitation and flushing and little attention was paid to them, but in relapses of the polyneuritis-and particularly in that of December 1964 and thereafter-these symptoms were increasingly obtrusive. They would occur at least once a day and at this time consisted of sinus tachycardia up to 140 per minute, dyspnoea, flushing, tremor of the hands, and blepharospasm, lasting up to 15 minutes and causing severedistress. In spite of the obvious evidence of organic disease, it was thought possible that these symptoms were psychogenic and accordingly an identically appearing placebo was gradually substituted for prednisolone and on 27 January 1965 the latter was stopped. At this point marked generalized weakness of the limbs was still present but she was able to walk. The attacks continued. On 10 March 1965 she was admitted with severe generalized weakness, the legs being almost paralysed and speech 330 
, and 180 mg/100 ml. were obtained at 30 minute intervals, glucose being present in the urine at one hour.
In view of the abnormal glucose tolerance she was treated with chlorpropamide 100 mg a day and restricted carbohydrate. Blood sugar levels were immediately controlled but weakness rapidly increased and by 9 September 1967 she was almost helpless, although no respiratory weakness developed. On this date prednisolone 40 mg a day was begun (Fig. 3) and five days later the distal muscles of the arms were noted to be stronger. By 14 September 1967 she could feed herself and on 20 September 1967 she walked with help. Rapid improvement continued on a reduced dose of prednisolone and by November there was no weakness or sensory loss and the knee jerks had returned. A month later the dose was reduced to 2-5 mg a day but paraesthesiae returned and within two weeks there was again marked generalized limb weakness and distal sensory loss. She was readmitted and the dose was increased to 40 mg a day with slight improvement, but notable increase in strength did not occur until the dose was raised to 60 mg a day. This dose could not be maintained as she developed severe upper abdominal pain, not improved by using enteric coated capsules, intermittent glycosuria, severe moon-face and an attack of pneumonia largely concealed by the corticosteroid therapy. Complete recovery of strength did not occur but there was considerable improvement. The dose was reduced to 7*5 mg a day in April 1968 but some toxic symptoms persisted. In June 1968 while on this dose she relapsed and within the course of 10 days again became bedridden. The dose was increased to 60 mg a day but an additional side-effect occurred, consisting of exceedingly severe headache on the slightest exertion. She was very weak and distressed by abdominal pain. Lumbar puncture was repeated and showed a pressure of 120 mm CSF and a protein of 35 mg/100 ml. in the CSF. Corticotrophin 40 units twice a day was added to the treatment and the prednisolone was reduced and stopped in the course of three weeks. 4 The headaches and abdominal pain subsided and strength improved. In the succeeding eight months her condition fluctuated, apparently in close relation to the dose of corticotrophin. Increased weakness could be relieved by 30 units a day and in February 1969, after a month's such treatment, there was almost complete clinical remission. This dose caused exacerbation of the diabetes and severe distortion of the face.
The polyneuritis in this case, therefore, responded repeatedly to prednisolone in increasing doses but intolerable side-effects led to reduction of dosage and relapse. Corticotrophin was also effective and less toxic. Nerve action potentials could seldom be obtained. A potential was recorded from the ulnar nerve at the elbow when stimulating the fifth digit in case I at a time when she had sensory symptoms but no sensory loss. Later in the disease no potential could be recorded and none was found at any stage in cases 2 and 3.
Motor conduction velocity was much reduced. In cases 1 and 3 fluctuations in the clinical state did not appear to influence the progressive decline in velocity (Table 1 ). In case 2 serial recordings were made over four years. In short-lived remissions conduction velocity altered little but sustained improvement occurred during the prolonged remission of 1967-68, although completely normal figures were not obtained even when motor power had been normal for several months (Fig. 4. ) The right brachial plexus, the main nerve trunks in the upper arm, and the median nerve in the forearm and right tibial nerves were sectioned. Changes were least marked in the nerve roots but more peripherally the abnormalities were uniformly distributed. Axons appeared normal. In cross-sections myelin sheaths were numerous but thin. Single fibre preparations stained with osmium tetroxide showed great variation in segmental length and in thickness of the myelin sheath. The epineurium and perineurium were not thickened.
Large quantities of amorphous material were found to be distending the perineurium and often separating the individual nerve fibres (Figs 5 and 6 ). Muscle spindles contained and sometimes appeared to be distended by similar material lying between the capsule and the endomysium of the intrafusal fibres (Fig. 7) . (Ravn, 1967) , but at no point is it possible to divide the acute from the chronic form except by arbitrary decision (Matthews, 1952) . Facial palsy is uncommon in chronic cryptogenic polyneuritis (Barraine, 1965) and the protein level in the cerebrospinal fluid is often normal, as in two of the present cases, but these distinctions are inconstant. Thickening of nerve trunks is not confined to chronic polyneuritis but may occur in acute attacks (Nattrass, 1921) . In addition to these difficulties in making a valid clinical distinction between acute and chronic forms there is growing evidence of a continuing disease process in the Guillain-Barre syndrome, even when complete clinical recovery may have occurred. Relapse and recurrence are well known (Jean, 1959 (Jean, 1959) and it is also known that such cases may be entirely uninfluenced by treatment (Ashworth and Smyth, 1969 (Austin, 1958) and there are few detailed descriptions fulfilling these criteria, Of the present cases the response to treatment in case 1 was never as rapid as in Austin's (1958) patient and dependence does not seem to have been immediately established, but the eventual speed and severity of relapse on reduction of dose left no doubt of the efficacy of corticosteroids. In cases 2 and 3 improvement on treatment or on increasing the dose was more rapid and relapse on reduction equally impressive. The management of these patients was exceedingly diffi-ult. In case 1 moderate corticosteroid dosage produced moderate improvement with relapse when the dose was reduced or stopped because of severe hypercorticoid changes. Eventually prolonged high dosage produced a most striking improvement but reduction because of grotesque distortion of the face was swiftly followed by relapse with fatal respiratory paralysis. In case 2 the pattern was similar, with increasing doses required to induce remission and severe relapse if the dose was too low. The patient developed troublesome diabetes and prolonged high doses of corticosteroids were clearly undesirable. Guided by our experience in case 1 the dose was reduced very gradually and only after full return of motor power had been present for some months. These precautions did not prevent relapse, although its severity could be controlled. The application of this painfully acquired knowledge to the management of case 3 was frustrated by the toxic effects of prednisolone. Remission was rapid and repeated but intolerable side-effects necessitated a change to corticotrophin. This was also obviously effective but improvement remained critically related to dosage.
It is clearly impossible to weigh the effects of treatment against the probable state of the patients if left untreated. Although in remission they were often almost free from symptons, in relapse they were far more gravely ill than when treatment was begun. We are in no doubt that corticosteroid dependence is a highly dangerous condition. It is possible that high initial doses rather than the smallest dose found to produce improvement would have been a more effective method of treatment.
In retrospect there were no features by which either the initial response to treatment or the development of dependence could have been predicted. In Table 2 (1969) and the altered vascular permeability proposed by Krucke (1941) to account for the amorphous material are both processes that might be influenced by corticosteroids, but there is no evidence of any difference in pathology between those cases that respond to treatment and those that do not. Nor has it been possible to determine which aspects of the pathological process are influenced by treatment as there are obvious objections to serial nerve biopsies even if the specimens obtained were comparable. The recovery of motor power while nerve conduction is still greatly slowed has been observed during remyelination in experimental neuropathy (Morgan-Hughes, 1968) , but rapid repeated changes in clinical state in response to treatment as in case 3 can only doubtfully be attributed to fluctuations in the degree of myelination.
Conduction block due to oedema of the nerve trunks might be susceptible to more rapid change. The abnormal intraneural material has often been described in hypertrophic polyneuritis (Austin, 1956 ). It is not confined to corticosteroid-dependent or responsive cases.
We conclude that there is no clinical, electrophysiological, or histological evidence from our material that would permit the prediction of corticosteroid dependence and that, apart from the response to treatment, there is no evidence that this is a distinct form of polyneuritis. The possible development of a state in which there may be no evasion of the dilemma of intolerable toxicity or severe paralysis should be remembered when the merits of corticosteroid treatment of chronic polyneuritis are considered.
